Denali plans to proceed medical building of DNL593, which is designed to ship progranulin to the mind the use of TransportVehicle™ technologyResults from ongoing Segment 1/2 find out about in sufferers with FTD-GRN anticipated via the top of 2026
SOUTH SAN FRANCISCO, Calif., April 03, 2026 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI) lately introduced that it has gained notification from Takeda of its resolution to terminate the collaboration settlement between the 2 corporations to co-develop and co-commercialize DNL593 (PTV:PGRN). The verdict was once pushed via strategic issues and isn’t associated with efficacy or protection information. DNL593 is an investigational progranulin alternative remedy using Denali’s Protein TransportVehicle™ (PTV) to ship progranulin around the blood-brain barrier to the mind for the remedy of frontotemporal dementia-granulin (FTD-GRN). Denali has led building actions and can regain complete keep watch over of DNL593 and its highbrow assets portfolio.
“While we have greatly valued our partnership, we are pleased to regain full ownership of DNL593. We remain confident in the scientific rationale and the data generated to date, and we look forward to advancing DNL593 independently. We plan to report results from the ongoing Phase 1/2 trial by the end of 2026,” stated Ryan Watts, Ph.D., Leader Govt Officer of Denali Therapeutics. “Our TransportVehicle platform is the first FDA-approved blood-brain barrier-crossing technology, enabling a robust portfolio with broad potential across neurodegenerative diseases like frontotemporal dementia, where there are no currently approved treatment options to slow the progression of this devasting disease.”
As up to now disclosed, information from the continuing Segment 1/2 find out about of DNL593, together with biomarker effects, are anticipated via the top of 2026. Enrollment on this find out about is finished with a complete of 40 individuals with FTD-GRN. Intervening time effects from Section A of the Segment 1/2 find out about in wholesome volunteers demonstrated dose-dependent will increase in cerebrospinal fluid progranulin ranges, in line with powerful mind supply of DNL593. DNL593 was once typically smartly tolerated, and there were no vital protection alerts so far.
About Frontotemporal Dementia (FTD)
FTD is the most typical type of dementia in other folks underneath 60 years of age. Whilst the development of signs varies via particular person, FTD brings an inevitable decline in serve as at the side of adjustments in persona and social behaviors, and occasionally language and/or motor disorder. Mutations within the granulin (GRN) gene, which encodes the progranulin (PGRN) protein, typically lead to lowered ranges of PGRN and are among the most typical genetic reasons of FTD. There are these days no licensed medicines to forestall or gradual the development of FTD or FTD-GRN.
Concerning the Denali TransportVehicle™ Platform
The blood-brain barrier (BBB) is very important in keeping up the mind’s microenvironment and protective it from destructive components and pathogens circulating within the bloodstream. Traditionally, the BBB has posed vital demanding situations to drug building for central apprehensive device sicknesses via fighting maximum medication from achieving the mind in therapeutically related concentrations. Denali’s TransportVehicle™ (TV) platform is a proprietary era designed to successfully ship huge healing molecules corresponding to antibodies, enzymes and oligonucleotides right through the entire frame, together with the mind, via crossing the BBB after intravenous management. The TV platform is in accordance with engineered Fc domain names that bind to express herbal delivery receptors, corresponding to transferrin receptor and CD98 heavy chain amino acid transporter, which can be expressed on the BBB and ship the TV and its healing shipment to the mind thru receptor-mediated transcytosis. In animal fashions, antibodies and enzymes engineered with the TV platform show greater than 10- to 30-fold higher mind publicity than an identical antibodies and enzymes with out this era. Oligonucleotides engineered with the TV platform show greater than a 1,000-fold higher mind publicity in primates than systemically delivered oligonucleotides with out this era. Advanced publicity and huge distribution within the mind would possibly building up healing efficacy via enabling standard fulfillment of therapeutically related concentrations of product applicants. The TV platform has been clinically validated and 5 TV-enabled techniques are these days in medical building.
About Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology corporate pioneering a brand new magnificence of biotherapeutics designed to move the blood-brain barrier the use of its proprietary TransportVehicle™ platform. With a clinically validated supply platform and a rising portfolio of healing applicants throughout all phases of building, Denali is advancing towards its purpose of turning in efficient medications to develop into existence for other folks with neurodegenerative sicknesses, lysosomal garage issues and different critical sicknesses. For more info, please discuss with www.denalitherapeutics.com.
Ahead-Taking a look Statements
This press liberate comprises forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements expressed or implied on this press liberate come with, however don’t seem to be restricted to, plans, timelines and expectancies associated with Denali’s TransportVehicle™ platform, together with its doable utility throughout present and long term product applicants and its talent to ship therapeutics to the mind; plans, timelines and expectancies associated with DNL593, together with the timing and availability of information readouts from the continuing Segment 1/2 find out about, the importance of intervening time information from the Segment 1/2 find out about together with with recognize to tolerability and protection, and the prospective healing advantage of DNL593; and statements via Denali’s Leader Govt Officer. Precise effects would possibly range materially from the ones expressed or implied via those forward-looking statements because of plenty of dangers and uncertainties. Those come with, however don’t seem to be restricted to, uncertainties associated with the FDA’s insurance policies and sped up approval program; dangers coming up from hostile financial prerequisites and their affect on Denali’s industry and operations; the potential for occasions or adjustments that would result in the termination of Denali’s collaboration agreements; demanding situations related to Denali’s transition to a business corporate; the facility of Denali and its collaborators to finish the improvement and, if licensed, the commercialization of product applicants; difficulties in affected person enrollment for ongoing and long term medical trials; whether or not the present ongoing trials had been powered sufficiently to show approvability to regulatory companies; reliance on third-party producers and providers for medical trial fabrics; dependence at the a hit building of Denali’s blood-brain barrier platform era and linked techniques; doable delays or screw ups in assembly anticipated medical trial timelines; the chance that promising preclinical profiles might not be replicated in medical settings; discrepancies between preclinical, early-stage or initial medical effects and results from later-stage trials; the prevalence of vital hostile occasions or different unwanted unwanted effects; the uncertainty surrounding regulatory approvals required for commercialization within the U.S., Europe or different global jurisdictions; Denali’s talent to advance a pipeline of product applicants or grow commercially a hit merchandise; traits in relation to Denali’s competition and its business, together with competing product applicants and remedies; Denali’s talent to procure, handle or offer protection to highbrow assets rights associated with its product applicants; the implementation and good fortune of Denali’s strategic plans for its industry, product applicants and blood-brain barrier platform era; Denali’s talent to procure further capital to finance its operations, as wanted; Denali’s talent to as it should be forecast long term monetary ends up in the present atmosphere; and different dangers and uncertainties, together with the ones described in Denali’s most up-to-date Annual and Quarterly Stories on Shape 10-Okay filed with the Securities and Trade Fee (SEC) on February 26, 2026, and Denali’s long term reviews to be filed with the SEC. With the exception of for AVLAYAH™ (tividenofusp alfa-eknm), Denali’s product applicants are investigational, and their protection and efficacy profiles have no longer but been established. Denali does no longer adopt any legal responsibility to replace or revise any forward-looking statements, to adapt those statements to exact effects or to make adjustments in Denali’s expectancies, except for as required via legislation.
